Ticker HubNYSE American

AZTR

Azitra Inc

PHARMACEUTICAL PREPARATIONSLatest regular mover

Latest price

$1.36+90.20%

As of Oct 26, 2026, 6:58 PM EDT · Market data by Massive

Market cap

$9.3M

Volume

148M

Previous close

$0.7150

Day range

$0.9062 – $2.13

Listed

Jun 16, 2023

Coverage

1 article

Price performance

Recent trading

5 trading days · 15-minute intervals · ET

Five-day open $0.8949Latest interval $1.33

Newsroom

Latest AZTR coverage

Oct 26, 2026

Midday Movers: AZTR, RCT, CLRO Lead the Small-Cap Scan

AZTR led a group of 10 active small-cap stocks flagged for editorial review.

AZTRRCTCLROSPRC

Recent catalyst headlines

Azitra, Inc. Announces Revitalizing Results from Ex Vivo Study of ATR-COSF Demonstrating Ability to Reduce Fine Lines and Improve Elasticity in Human Skin

Oct 26, 2026

Azitra, Inc. Announces Reverse Stock Split

Oct 16, 2026

AZTR: Updated Valuation Reflects Cosmetic and EGFRi Rash Programs

Sep 28, 2026

Company overview

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 13
Headquarters: BRANFORD, CT
CIK: 0001701478

Company website View advanced chart

SEC filings

No filing records are attached to this profile yet.

Browse EDGAR

Profile at a glance

Jun 16, 2023

Listed

Employees

Market data may be delayed and is provided for informational purposes only. SmallCapsDaily content is not investment advice.